CAPR AdComm — Jul 29, 2026
Capricor Therapeutics · Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC).
Meeting dateJul 29, 2026
CommitteeCTGTAC
CompanyCapricor Therapeutics
DrugDeramiocel (CAP-1002)
IndicationDuchenne muscular dystrophy (DMD)
PDUFA dateAug 22, 2026
ApplicationBLA 125842
Primary sourceFDA Federal Register notice →
An advisory committee vote is a public panel review; it is advisory only — the FDA makes the final decision at the PDUFA date. All AdComm meetings →
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. © 2026 pdufa.bio